SONOSCAPE(SZ:300633) Zheng Quan Shi Bao Wang·2025-04-26 05:44Core Insights - The company reported a decline in both revenue and net profit for Q1 2025, with revenue at 430 million yuan and net profit at 8.07 million yuan, indicating a year-on-year decrease [1] - The company is focusing on multi-product line strategies and high-intensity strategic investments, aiming for sustained performance growth in 2025 through high-end and specialized product development [1] - The domestic medical equipment procurement market is expected to grow by over 20% this year, driven by a significant increase in hospital procurement scale and a surge in project approvals [1] Financial Performance - In Q1 2025, the company achieved revenue of 430 million yuan and a net profit of 8.07 million yuan, both showing a certain degree of decline compared to the previous year [1] - The company's R&D investment reached 126 million yuan in Q1, reflecting a year-on-year increase of 23.7% [1] Product Development - The company has launched several key products, including the 4K iEndo smart endoscope platform and the "Lingzhu" 4K 3D fluorescence imaging platform, enhancing its competitive edge in minimally invasive surgery [2] - The integration of AI and medical devices is being emphasized, with the company aiming to create a new engine for intelligent development [1][2] Market Position - The company is witnessing an increase in market share in ultrasound and endoscopy businesses, with a strategic focus on minimally invasive surgery and cardiovascular intervention products [2] - The company aims to establish a comprehensive multi-product line development framework, combining internal and external medicine, diagnosis and treatment, as well as equipment and consumables [2]